Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant

Area of Science:

• Urology
• Oncology
• Medical treatment

Background:

• Current treatment paradigms for invasive bladder cancer are often outdated.
• A standardized approach to radical surgery, chemotherapy, or radiation is insufficient.
• Individualized treatment strategies are necessary, considering patient-specific factors.

Purpose of the Study:

• To emphasize the need for personalized treatment plans in invasive bladder cancer.
• To explore the role of neoadjuvant therapy and bladder preservation strategies.
• To highlight challenges and future directions in optimizing invasive bladder cancer therapy.

Main Methods:

• Review of current treatment approaches for invasive bladder cancer.
• Discussion of neoadjuvant therapy, chemotherapy, radiation, and surgical options.
• Analysis of therapeutic goals, including bladder preservation and micrometastasis treatment.

Main Results:

• Neoadjuvant therapy offers in vivo response evaluation and potential for bladder preservation.
• Treatment selection should be based on tumor stage (T2/T3a vs. higher stages) and therapeutic goals.
• Initial surgery may be beneficial for some patients to establish prognosis.
• Postoperative chemotherapy is recommended for patients with positive nodes.
• Drug resistance remains a significant challenge, necessitating further research.

Conclusions:

• A personalized, multimodal approach is crucial for invasive bladder cancer treatment.
• Defining clear therapeutic goals is paramount before initiating treatment.
• Further research and large-scale randomized trials are required to address patient heterogeneity and optimize individual therapies.